Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

Li, Shutong; Wang, Aoxue; Wu, Yongya; He, Shengyuan; Shuai, Wen; Zhao, Min; Zhu, Yumeng; Hu, Xiuying; Luo, Yubin; Wang, Guan

doi:10.1111/imr.13274

Cited by 6 publications

(5 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non‐small cell lung cancer (NSCLC) is a common type of lung cancer. [ 1,2 ] Surgery is the main treatment for NSCLC, however, patients with locally advanced NSCLC still face a high risk of recurrence and metastasis after surgery. [ 3,4 ] Therefore, exploring the potential molecular targets that affect the progression of NSCLC may provide new biomarkers for the treatment of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Liu,

Wu,

Wang

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Circular RNA is an important regulator for non‐small cell lung cancer (NSCLC). Circ_0000735 has been found to be significantly overexpressed in NSCLC tissues. Therefore, its role and mechanism in NSCLC progression need to be further explored. The expression levels of circ_0000735, miR‐345‐5p and A disintegrin and metalloprotease 19 (ADAM19) were determined using quantitative real‐time PCR. EdU staining, wound healing and transwell assays were utilized to detect cell proliferation and metastasis. The protein levels of metastasis markers, exosome markers and ADAM19 were determined using western blot. Animal experiments were performed to confirm the role of circ_0000735 in NSCLC tumorigenesis. The exosomes from cells and serum were identified using transmission electron microscopy and nanoparticle tracking analysis. We found that circ_0000735 was upregulated in NSCLC, and its knockdown repressed NSCLC cell proliferation and metastasis. In terms of mechanism, circ_0000735 targeted miR‐345‐5p to regulate ADAM19. MiR‐345‐5p inhibitor reversed the suppressive effect of circ_0000735 knockdown on NSCLC progression, and ADAM19 overexpression abolished the inhibition effect of miR‐345‐5p on NSCLC progression. Also, animal experiments showed that silencing of circ_0000735 reduced NSCLC tumorigenesis. In addition, exosomes mediated the intercellular transmission of circ_0000735, and serum exosomal circ_0000735 might be an important indicator for the diagnosis of NSCLC. In conclusion, circ_0000735 facilitated NSCLC progression via miR‐345‐5p/ADAM19 pathway, and serum exosomal circ_0000735 might be a potential biomarker for NSCLC diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Liu,

Wu,

Wang

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…Pathologically, lung cancers are classified into small-cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC). Of these, about 85% of lung cancers are NSCLCs, which include lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [ 2 ]. Patients diagnosed with lung cancer typically exhibit advanced-stage disease, often accompanied by distant metastases at the onset of symptoms.…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Ren,

Fei,

Qiu

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still a potential means of eradicating lung cancer, patients with advanced lung cancer usually miss the best chance for surgical treatment, and even after surgical resection patients may still experience tumor recurrence. Additionally, chemotherapy, the mainstay of treatment for patients with advanced lung cancer, has the potential to be chemo-resistant, resulting in poor clinical outcomes. The emergence of liquid biopsies has garnered considerable attention owing to their noninvasive nature and the ability for continuous sampling. Technological advancements have propelled circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and tumor-associated antigens (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, tumor metabolites, TAAs and TEPs. Furthermore, we expound on the practical applications of liquid biopsies, including early diagnosis, treatment response monitoring, prognostic evaluation, and recurrence monitoring in the context of lung cancer.

show abstract

“…Cell death is fundamental for the development and homeostasis of organisms. [1][2][3] Necroptosis is a caspase-independent modality of programmed cell death (PCD), which was first proposed by Degterev in 2005. 4,5 Necroptosis can be initiated by death receptors and pathogen receptors, involving clumping dying cells, rupture of cell membrane, swelling of cell bodies and organelles, and inflammasome formation.…”

Section: Introductionmentioning

confidence: 99%

“…Cell death is fundamental for the development and homeostasis of organisms 1–3 . Necroptosis is a caspase‐independent modality of programmed cell death (PCD), which was first proposed by Degterev in 2005 4,5 .…”

Section: Introductionmentioning

confidence: 99%

Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases

Guo,

Zhou,

Wang

et al. 2023

Immunological Reviews

View full text Add to dashboard Cite

SummaryNecroptosis is generally considered as an inflammatory cell death form. The core regulators of necroptotic signaling are receptor‐interacting serine–threonine protein kinases 1 (RIPK1) and RIPK3, and the executioner, mixed lineage kinase domain‐like pseudokinase (MLKL). Evidence demonstrates that necroptosis contributes profoundly to inflammatory respiratory diseases that are common public health problem. Necroptosis occurs in nearly all pulmonary cell types in the settings of inflammatory respiratory diseases. The influence of necroptosis on cells varies depending upon the type of cells, tissues, organs, etc., which is an important factor to consider. Thus, in this review, we briefly summarize the current state of knowledge regarding the biology of necroptosis, and focus on the key molecular mechanisms that define the necroptosis status of specific cell types in inflammatory respiratory diseases. We also discuss the clinical potential of small molecular inhibitors of necroptosis in treating inflammatory respiratory diseases, and describe the pathological processes that engage cross talk between necroptosis and other cell death pathways in the context of respiratory inflammation. The rapid advancement of single‐cell technologies will help understand the key mechanisms underlying cell type‐specific necroptosis that are critical to effectively treat pathogenic lung infections and inflammatory respiratory diseases.

show abstract

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

Cited by 6 publications

References 188 publications

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases

Contact Info

Product

Resources

About